Lewandowska Katarzyna, Lewandowska Anna, Baranska Inga, Klatt Magdalena, Augustynowicz-Kopec Ewa, Tomkowski Witold, Szturmowicz Monika
1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Department of Radiology, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.
Diagnostics (Basel). 2022 Apr 7;12(4):922. doi: 10.3390/diagnostics12040922.
Intra-vesical instillations with bacillus Calmette-Guerin (BCG) are the established adjuvant therapy for superficial bladder cancer. Although generally safe and well tolerated, they may cause a range of different, local, and systemic complications. We present a patient treated with BCG instillations for three years, who was admitted to our hospital due to fever, hemoptysis, pleuritic chest pain and progressive dyspnea. Chest computed tomography (CT) showed massive bilateral ground glass opacities, partly consolidated, localized in the middle and lower parts of the lungs, bronchial walls thickening, and bilateral hilar lymphadenopathy. PCR tests for SARS-CoV-2 as well as sputum, blood, and urine for general bacteriology-were negative. Initial empiric antibiotic therapy was ineffective and respiratory failure progressed. After a few weeks, a culture of complex was obtained from the patient's specimens; the cultured strain was identified as BCG. Anti-tuberculous treatment with rifampin (RMP), isoniazid (INH) and ethambutol (EMB) was implemented together with systemic corticosteroids, resulting in the quick improvement of the patient's clinical condition. Due to hepatotoxicity and finally reported resistance of the BCG strain to INH, levofloxacin was used instead of INH with good tolerance. Follow-up CT scans showed partial resolution of the pulmonary infiltrates. BCG infection in the lungs must be taken into consideration in every patient treated with intra-vesical BCG instillations and symptoms of protracted infection.
卡介苗(BCG)膀胱内灌注是浅表性膀胱癌既定的辅助治疗方法。尽管通常安全且耐受性良好,但它们可能会引起一系列不同的局部和全身并发症。我们报告了一名接受BCG灌注治疗三年的患者,该患者因发热、咯血、胸膜炎性胸痛和进行性呼吸困难入院。胸部计算机断层扫描(CT)显示双侧大片磨玻璃影,部分实变,位于肺中下部,支气管壁增厚,双侧肺门淋巴结肿大。新型冠状病毒肺炎(SARS-CoV-2)的聚合酶链反应(PCR)检测以及痰液、血液和尿液的一般细菌学检测均为阴性。初始经验性抗生素治疗无效,呼吸衰竭进展。几周后,从患者标本中培养出一种复合菌;培养菌株被鉴定为BCG。实施利福平(RMP)、异烟肼(INH)和乙胺丁醇(EMB)的抗结核治疗并联合全身使用皮质类固醇,患者的临床状况迅速改善。由于肝毒性以及最终报告BCG菌株对INH耐药,改用左氧氟沙星替代INH,耐受性良好。随访CT扫描显示肺部浸润部分消退。对于每一位接受膀胱内BCG灌注治疗且有长期感染症状的患者,都必须考虑肺部BCG感染。